Literature DB >> 3994351

Antimicrobial activity of HR810 against 419 strict anaerobic bacteria.

R N Jones, E H Gerlach.   

Abstract

HR810 and four other new beta-lactams were tested against 419 recent clinical anaerobic bacterial isolates. HR810 was found to have an antimicrobial spectrum most similar to that of cefotaxime, inhibiting 52.6% of Bacteroides fragilis group strains and 97.2% of all other anaerobic strains at an MIC of less than or equal to 16 micrograms/ml. Cefoxitin was found to have a narrower antimicrobial spectrum against the gram-positive anaerobic bacteria (8.4 to 10.1% less) than HR810 and cefotaxime, respectively.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3994351      PMCID: PMC176287          DOI: 10.1128/AAC.27.3.413

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Susceptibility of gram-positive aerobic cocci to the new cephalosporin HR 810.

Authors:  A Bauernfeind
Journal:  Eur J Clin Microbiol       Date:  1983-08       Impact factor: 3.267

2.  HR 810, a cephalosporin with low affinity for Enterobacter cloacae beta-lactamase.

Authors:  R M Tolxdorff-Neutzling; B Wiedemann
Journal:  Eur J Clin Microbiol       Date:  1983-08       Impact factor: 3.267

3.  The activity of nitro-compounds against Bacteroides fragilis is related to their electron affinity.

Authors:  A V Reynolds
Journal:  J Antimicrob Chemother       Date:  1981-08       Impact factor: 5.790

4.  The activity of cefotaxime and desacetylcefotaxime alone and in combination against anaerobes and staphylococci.

Authors:  R N Jones; A L Barry; R R Packer
Journal:  Diagn Microbiol Infect Dis       Date:  1984-06       Impact factor: 2.803

5.  In vitro evaluation of HR810, a new wide-spectrum aminothiazolyl alpha-methoxyimino cephalosporin.

Authors:  R N Jones; C Thornsberry; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

6.  Susceptibility of the Bacteroides fragilis group in the United States in 1981.

Authors:  F P Tally; G J Cuchural; N V Jacobus; S L Gorbach; K E Aldridge; T J Cleary; S M Finegold; G B Hill; P B Iannini; R V McCloskey; J P O'Keefe; C L Pierson
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

7.  Cefoxitin inactivation by Bacteroides fragilis.

Authors:  G J Cuchural; F P Tally; N V Jacobus; P K Marsh; J W Mayhew
Journal:  Antimicrob Agents Chemother       Date:  1983-12       Impact factor: 5.191

8.  The Antibacterial activity in vitro and beta-lactamase stability of the new cephalosporin HR 810 in comparison with five other cephalosporins and two aminoglycosides.

Authors:  G Seibert; M Limbert; I Winkler; T Dick
Journal:  Infection       Date:  1983 Sep-Oct       Impact factor: 3.553

9.  In vitro activity of HR 810, a new broad-spectrum cephalosporin.

Authors:  K Machka; I Braveny
Journal:  Eur J Clin Microbiol       Date:  1983-08       Impact factor: 3.267

10.  Disk diffusion testing, quality control guidelines, and antimicrobial spectrum of HR810, a fourth-generation cephalosporin, in clinical microbiology laboratories.

Authors:  R N Jones; C Thornsberry; A L Barry; L Ayers; S Brown; J Daniel; P C Fuchs; T L Gavan; E H Gerlach; J M Matsen
Journal:  J Clin Microbiol       Date:  1984-09       Impact factor: 5.948

View more
  4 in total

Review 1.  In vitro antibacterial effects of cephalosporins.

Authors:  J D Williams; F Moosdeen
Journal:  Drugs       Date:  1987       Impact factor: 9.546

2.  Antibacterial activities in vitro and in vivo and pharmacokinetics of cefquinome (HR 111V), a new broad-spectrum cephalosporin.

Authors:  M Limbert; D Isert; N Klesel; A Markus; K Seeger; G Seibert; E Schrinner
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

3.  In vitro and in vivo antibacterial activities of E1077, a novel parenteral cephalosporin.

Authors:  T Toyosawa; S Miyazaki; A Tsuji; K Yamaguchi; S Goto
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

4.  The synergistic effect of cefotaxime and desacetylcefotaxime against clinical isolates of anaerobic bacteria.

Authors:  H R Devlin; L Boskovski
Journal:  Drugs       Date:  1988       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.